Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309 is registered in ClinicalTrials.gov with NovaDigm Therapeutics, Inc. as lead sponsor.

NCT NCT03455309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization
Lead sponsor
NovaDigm Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2018
Completion date
October 15, 2019
Enrollment
382 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus